http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html si-local-file:///var/storage/secattach/20260814/26931402.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html Fri, 14 Aug 2026 16:31:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html si-local-file:///var/storage/secattach/20260814/26931402.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html Fri, 14 Aug 2026 16:31:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html si-local-file:///var/storage/secattach/20260814/26931402.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+TCG+Crossover+GP+I%2C+LLC/26931402.html Fri, 14 Aug 2026 16:31:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html si-local-file:///var/storage/secattach/20260813/26918356.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html Thu, 13 Aug 2026 10:55:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html si-local-file:///var/storage/secattach/20260813/26918356.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html Thu, 13 Aug 2026 10:55:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html si-local-file:///var/storage/secattach/20260813/26918356.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Abivax+S.A.++++++++++++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918356.html Thu, 13 Aug 2026 10:55:00 -0400 ABVX ABVX O.17222435 http://www.streetinsider.com/Corporate+News/Abivax+completes+pre-NDA+meeting+with+FDA+for+ulcerative+colitis+drug/26843576.html <p>Abivax SA (Nasdaq: ABVX) announced it has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for obefazimod, its drug candidate for the treatment of adults with moderately to severely active ulcerative colitis.</p><p>According to a statement from the company, the FDA provided feedback that resulted in alignment on the planned NDA submission strategy, including the content and format of the submission. Abivax said it remains on track to file its first NDA for obefazimod by the end of 2026.</p><p>Marc de Garidel, Chief Executive Officer of Abivax, said: "Achieving alignment with the FDA on our http://www.streetinsider.com/Corporate+News/Abivax+completes+pre-NDA+meeting+with+FDA+for+ulcerative+colitis+drug/26843576.html Thu, 30 Jul 2026 16:07:24 -0400 ABVX http://www.streetinsider.com/FDA/Abivax+completes+pre-NDA+meeting+with+FDA+for+ulcerative+colitis+drug/26843576.html <p>Abivax SA (Nasdaq: ABVX) announced it has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for obefazimod, its drug candidate for the treatment of adults with moderately to severely active ulcerative colitis.</p><p>According to a statement from the company, the FDA provided feedback that resulted in alignment on the planned NDA submission strategy, including the content and format of the submission. Abivax said it remains on track to file its first NDA for obefazimod by the end of 2026.</p><p>Marc de Garidel, Chief Executive Officer of Abivax, said: "Achieving alignment with the FDA on our http://www.streetinsider.com/FDA/Abivax+completes+pre-NDA+meeting+with+FDA+for+ulcerative+colitis+drug/26843576.html Thu, 30 Jul 2026 16:07:24 -0400 ABVX http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Press+Releases/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html <p align="center"><b>Abivax Announces Positive Pre-NDA </b><b>Interaction with the FDA for Obefazimod</b></p> <p align="center"><i>Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026</i></p> <p align="justify"><b>PARIS, France – July 30, 2026 – 10:05 p.m. CEST</b> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=KmygmJaiY5aeeB8E5kVOeVsUE7wqTY4WDszWoHGU74MDaN7qQuNfThU18KXh4BFHhdiK7ri-Xr96VmULH1Xx8A==" rel="nofollow" target="_blank">Abivax SA</a> (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced http://www.streetinsider.com/Globe+Newswire/Abivax+Announces+Positive+Pre-NDA+Interaction+with+the+FDA+for+Obefazimod/26843503.html Thu, 30 Jul 2026 16:05:00 -0400 A.06822034 A.26800952 ABVX ABVX O.00711722 O.17222435 O.20026344 http://www.streetinsider.com/Analyst+PT+Change/Abivax+%28ABVX%29+PT+Raised+to+%24180+at+Morgan+Stanley/26811471.html Morgan Stanley analyst Judah Frommer raised the price target on Abivax (NASDAQ: ABVX) to $180.00 (from $132.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Abivax+%28ABVX%29+PT+Raised+to+%24180+at+Morgan+Stanley/26811471.html Fri, 24 Jul 2026 09:38:19 -0400 ABVX http://www.streetinsider.com/Corporate+News/Abivax+names+four+commercial+leaders+ahead+of+planned+NDA+filing/26808035.html <p>Abivax SA (Nasdaq: ABVX) has appointed four executives to its commercial leadership team as the company prepares for a potential U.S. commercialization of its drug candidate obefazimod, with a New Drug Application submission to the FDA planned for the fourth quarter of 2026.</p><p>According to a company statement, the four appointments are:</p><p><strong>James Berger</strong> as Global Head of Marketing. Berger previously served as Global Franchise Head for TEZSPIRE at Amgen and spent more than a decade at Takeda working on ENTYVIO. He also held roles at Merck and Bristol Myers Squibb.</p><p><strong>Ivan Nuñez-Pacheco</strong> as Global Head of Patient Services. Nuñez-Pacheco previously served as http://www.streetinsider.com/Corporate+News/Abivax+names+four+commercial+leaders+ahead+of+planned+NDA+filing/26808035.html Thu, 23 Jul 2026 16:06:14 -0400 ABVX http://www.streetinsider.com/Management+Changes/Abivax+names+four+commercial+leaders+ahead+of+planned+NDA+filing/26808035.html <p>Abivax SA (Nasdaq: ABVX) has appointed four executives to its commercial leadership team as the company prepares for a potential U.S. commercialization of its drug candidate obefazimod, with a New Drug Application submission to the FDA planned for the fourth quarter of 2026.</p><p>According to a company statement, the four appointments are:</p><p><strong>James Berger</strong> as Global Head of Marketing. Berger previously served as Global Franchise Head for TEZSPIRE at Amgen and spent more than a decade at Takeda working on ENTYVIO. He also held roles at Merck and Bristol Myers Squibb.</p><p><strong>Ivan Nuñez-Pacheco</strong> as Global Head of Patient Services. Nuñez-Pacheco previously served as http://www.streetinsider.com/Management+Changes/Abivax+names+four+commercial+leaders+ahead+of+planned+NDA+filing/26808035.html Thu, 23 Jul 2026 16:06:14 -0400 ABVX